EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer

Imane Boughazi, Chloe Chan, Marina Parton, Daniel L Morganstein

Endocrine Oncology · 20.11.2026

DOI: 10.1530/eo-26-0050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 20.11.2026. Verfasst von Imane Boughazi und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Summary Tucatinib is a highly selective, oral, reversible human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor approved for the treatment of metastatic HER2-positive breast cancer. While its established adverse effects include diarrhoea, hepatotoxicity, and palmar-plantar erythrodysesthesia, endocrine toxicities have not been described in the Summary of Product Characteristics (SPC) or published literature. We report a case of secondary adrenal insufficiency in a 73-year-old woman receiving Tucatinib in combination with Trastuzumab and Capecitabine. She developed worsening hyponatremia and biochemical evidence of central adrenal suppression without prior steroid or opioid exposure. Sodium normalized promptly with glucocorticoid replacement. Following discontinuation of Tucatinib, hypothalamic–pituitary–adrenal (HPA) axis function recovered, and steroid therapy was successfully withdrawn. This case highlights a previously unreported potential endocrine adverse effect of Tucatinib and underscores the importance of vigilance for adrenal dysfunction in patients receiving targeted therapies. Learning points:

Zitieren

APA

Boughazi, I., Chan, C., Parton, M., & Morganstein, D. L. (2026). Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer. Endocrine Oncology. https://doi.org/10.1530/eo-26-0050

Vancouver

Boughazi I, Chan C, Parton M, Morganstein DL. Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer. Endocrine Oncology. 2026. doi:10.1530/eo-26-0050

BibTeX
@article{Boughazi2026,
  author = {Boughazi, Imane and Chan, Chloe and Parton, Marina and Morganstein, Daniel L},
  title = {Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer},
  journal = {Endocrine Oncology},
  year = {2026},
  doi = {10.1530/eo-26-0050}
}
Kostenlos starten →